Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: how they work and when to use them.
a Centre for Lymphoid Cancer , British Columbia Cancer Agency , British Columbia , Canada.|b Department of Medical Oncology , British Columbia Cancer Agency , British Columbia , Canada.
Kerry J
KJ
Savage
a Centre for Lymphoid Cancer , British Columbia Cancer Agency , British Columbia , Canada.|c Department of Pathology and Laboratory Medicine , University of British Columbia , British Columbia , Canada.
Christian
C
Steidl
D006689:Hodgkin Disease; D006801:Humans; D008228:Lymphoma, Non-Hodgkin; D061026:Programmed Cell Death 1 Receptor
D061026:Programmed Cell Death 1 Receptor
Hodgkin lymphoma; Lymphoma; biomarker; checkpoint inhibition; clinical trial; microenvironment